
Systemic treatment with programmed death receptor 1 (PD‐1) inhibitors has been approved for patients with advanced cutaneous squamous cell carcinoma (cSCC) ineligible for curative surgery or radiation. The PD‐1 inhibitors cemiplimab and pembrolizumab showed a promising response rate of 50% and 38.5% respectively. Experience on its share in the treatment of cSCC of the head and neck region (cSCCHN) is limited. We hypothesised that PD‐1 inhibitors would have a limited place in clinical practice as a large proportion of patients with advanced disease is immunocompromised (e.g. organ transplant patients) and would have a contraindication for PD‐1 inhibitors.
Like
Save
Share